Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 40.4258
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 963348484992.0
- FreeCF/Share 10.0576
- PFCF 106.7931
- PE 52.2408
- Debt/Assets 0.3698
- DivYield 0.0056
- ROE 1.0226
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
| Downgrade | LLY | Daiwa Securities | Outperform | Neutral | -- | $700 | Aug. 18, 2025 |
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
News
Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments
Published: September 16, 2025 by: CNBC
Sentiment: Positive
Eli Lilly on Tuesday said it will spend $5 billion to build a manufacturing facility in Goochland County, Virginia, to boost production capacity for targeted cancer drugs and other treatments. The plant is the company's first of four planned U.S. manufacturing sites, which will begin making medicines within five years.
Read More
Lilly announces plans to build $5 billion manufacturing facility in Virginia
Published: September 16, 2025 by: PRNewsWire
Sentiment: Neutral
New site in Virginia's Goochland County will develop active pharmaceutical ingredients (API) in the U.S. for cancer, autoimmune and other advanced therapies Company will create 2,450 high-wage manufacturing and construction jobs This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year INDIANAPOLIS , Sept. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County.
Read More
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.
Read More
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
Published: September 12, 2025 by: CNBC
Sentiment: Neutral
Eli Lilly and Novo Nordisk are both preparing to launch obesity pills in the U.S. next year. Lilly expects results from a head-to-head trial of its pill orforglipron versus Novo's oral semaglutide in the coming months, said Lilly's Chief Scientific Officer Dan Skovronsky.
Read More
Lilly to participate in Bernstein's 2nd Annual Healthcare Forum
Published: September 11, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Sept. 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bernstein's 2nd Annual Healthcare Forum on September 25, 2025.
Read More
Novo Nordisk layoffs: 9,000 jobs cut as weight-loss drug competition with Eli Lilly heats up
Published: September 10, 2025 by: Fast Company
Sentiment: Negative
Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to encroach on its market share.
Read More
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Negative
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
Eli Lilly (LLY) Just Reclaimed the 50-Day Moving Average
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Eli Lilly (LLY) is looking like an interesting pick, as it just reached a key level of support. LLY recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Read More
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Sept 2025)
Published: September 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Read More
Our H2 2025 Top Ideas
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
The US economy is showing signs of slowing, with the labor market cooling, consumer sentiment weak, Q3 GDP expected to slow to ~1.3%, and inflation still above the Fed's 2% target. Stagflation is now becoming a real risk. Markets are expensive; the S&P 500 is near all-time highs, and broad-market ETFs like VOO, QQQ, and VTI may only deliver modest returns over the next few years.
Read More
LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
Read More
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
Read More
Eli Lilly launches AI platform for drug discovery
Published: September 09, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) has introduced Lilly TuneLab, an artificial intelligence and machine learning platform designed to support early-stage biotechnology companies in drug discovery. The system provides access to models trained on Lilly's proprietary datasets, which the company estimates represent more than $1 billion in research investment, the company said on Tuesday.
Read More
Eli Lilly And Company (LLY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Jacob Van Naarden - Executive VP & President of Lilly Oncology David Hyman - Chief Medical Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.
Read More
Eli Lilly And Company (LLY) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Published: September 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) 2025 Wells Fargo Healthcare Conference September 5, 2025 9:30 AM EDT Company Participants Patrik Jonsson - Executive VP & President of Lilly International Mike Czapar - Director of Investor Relations Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Good morning. Thank you very much for being here on a Friday.
Read More
Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day?
Published: September 05, 2025 by: The Motley Fool
Sentiment: Neutral
Eli Lilly (LLY 0.56%) is typically a market outperformer, but it has had a challenging year so far. Besides general market volatility, the company has dealt with clinical setbacks, lower-than-expected guidance, and the threat of tariffs.
Read More
Insider Watch: 3 CEOs Buying the Dip
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture.
Read More
Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly
Published: September 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Short LLY ETF (Ticker: LLYZ).
Read More
These 3 Companies are Seeing Supercharged Sales Growth
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth.
Read More
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
Read More
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
Read More
Cramer Loves These Dividend Stocks
Published: September 01, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points Jim Cramer's Mad Money offers insights valuable to income investors, despite his broader focus on growth.
Read More
Eli Lilly: Orals Unlock The Next Wave Of Obesity Drug Adoption
Published: August 28, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly and Company's orforglipron shows strong efficacy and manufacturing advantages over Novo Nordisk's oral semaglutide, supporting future growth in the obesity and diabetes market. Orforglipron's convenience, scalability, and potential dual-indication label position it as a key driver for Eli Lilly's revenue diversification and premium valuation. Despite payer coverage and tolerability challenges, the massive eligible population and orforglipron's advantages should drive exponential sales growth.
Read More
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.
Read More
LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.
Read More
Eli Lilly's Obesity Pill Breakthrough Shakes Up $150 Billion Weight-Loss Race
Published: August 27, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points in This Article: Eli Lilly's (LLY) Zepbound has outshone Novo Nordisk's Wegovy, achieving superior weight-loss results in clinical trials.
Read More
The bear case on Eli Lilly has played out, says only firm to have called it a sell
Published: August 27, 2025 by: Market Watch
Sentiment: Neutral
The bear case for Eli Lilly has now played out following the reaction to the drugmaker's oral obesity drug trial, an analyst said Wednesday in upgrading the stock.
Read More
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year landmark analysis of monarchE, treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit Results reinforce two years of Verzenio plus endocrine therapy as the standard of care in HR+, HER2-, node-positive, early breast cancer at a high risk of recurrence INDIANAPOLIS , Aug. 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the primary overall survival (OS) analysis of the Phase 3 …
Read More
Durable Goods Orders Decreased Less Than Expected
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Pre-market activity is somewhat better than earlier in the trading session this morning, following a less-bad Durable Goods report for July. We also appear to be bouncing around a bit more in recent trading days after a steadier level following August 2nd lows.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000